Entero Therapeutics, Inc.
ENTO
$0.545
$0.060712.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.98M | 14.72M | 16.22M | 16.96M | 16.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.34M | 15.62M | 18.51M | 20.05M | 20.81M |
| Operating Income | -7.34M | -15.62M | -18.51M | -20.05M | -20.81M |
| Income Before Tax | -7.47M | -15.62M | -18.53M | -20.06M | -20.82M |
| Income Tax Expenses | 4.26M | -10.60M | -10.60M | -10.60M | -14.86M |
| Earnings from Continuing Operations | -22.33 | -15.62 | -7.92 | -9.46 | -5.96 |
| Earnings from Discontinued Operations | -2.56M | -2.44M | -2.00M | -1.32M | -192.80K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.89M | -18.06M | -9.92M | -10.78M | -6.16M |
| EBIT | -7.34M | -15.62M | -18.51M | -20.05M | -20.81M |
| EBITDA | -7.34M | -15.61M | -18.46M | -19.99M | -20.77M |
| EPS Basic | -7.96 | -4.55 | -6.67 | -15.29 | -49.16 |
| Normalized Basic EPS | -1.02 | -4.12 | -7.71 | -13.12 | -35.24 |
| EPS Diluted | -8.00 | -7.30 | -9.42 | -18.04 | -51.91 |
| Normalized Diluted EPS | -1.02 | -1.29 | -4.87 | -10.28 | -32.41 |
| Average Basic Shares Outstanding | 15.05M | 12.04M | 9.39M | 5.22M | 3.03M |
| Average Diluted Shares Outstanding | 15.05M | 24.79M | 22.14M | 17.96M | 15.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |